THERATOPE

Known as: Theratope STn-KLH Vaccine 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2012
01219962012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Changes in the composition of glycans added to glycoproteins and glycolipids are characteristic of the change to malignancy… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2004
Review
2004
Cancer vaccines have demonstrated that they can stimulate antibody and cell-mediated immune responses against tumor-associated… (More)
Is this relevant?
2004
2004
2547 Background: Theratope is an investigational therapeutic cancer vaccine consisting of a synthetic form of STn conjugated to… (More)
Is this relevant?
2003
2003
The success of high-dose chemotherapy followed by autologous stem-cell rescue as treatment for breast and ovarian cancer is… (More)
Is this relevant?
Review
2003
Review
2003
  • Drugs in R&D
  • 2003
Biomira is developing a therapeutic cancer vaccine [THERATOPE] for treatment of breast and other cancers. This profile has been… (More)
Is this relevant?
Review
2003
Review
2003
The development of active specific immunotherapy depends on the identification of altered cancer cell-specific molecules or… (More)
Is this relevant?
Review
2003
Review
2003
Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated. Expression… (More)
Is this relevant?
Review
2001
Review
2001
Active specific immunotherapy (ASI) is a promising approach to treating cancer. Numerous studies in the laboratory have… (More)
Is this relevant?
Review
2000
Review
2000
Active specific immunotherapy, the use of 'vaccines' to stimulate therapeutic tumor antigen-specific immune responses, holds… (More)
Is this relevant?
1996
1996
THERATOPE (Biomira Inc., Edmonton, AB, Canada) STn-KLH cancer vaccine induces strong antibody titers against both the synthetic… (More)
Is this relevant?